Serum Insulin and Growth Hormone Response to Arginine Infusion in Healthy and Psoriatic Persons

Abstract

Serum insulin and growth hormone responses to intravenous infusion of arginine were measured in 10 normal control persons and 13 age- and weight-matched nondiabetic psoriatics. The average peak insulin levels, 58.2 μU/ml for normal controls and 47.8 μU/ml for the psoriatics, were recorded at 30 min. The average growth hormone peak values, 20.1 ng/ml for normal controls and 17.8 ng/ml for the psoriatics, were recorded in most cases in 60 min. No significant differences were obtained between the normal controls and psoriatics.

Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis

“…Despite the increased risk of type 2 diabetes, there have been few investigations of the characteristics of glucose metabolism in patients with psoriasis. Most previous clinical studies studying glucometabolic disturbances in psoriasis have used suboptimal methodology and focused on insulin sensitivity [28][29][30][31][32] or pancreatic beta-cell function [30,[32][33][34][35]. The results are conflicting and difficult to compare due to methodological differences across studies.…”